A number of preclinical studies have detected regulatory factors for Nrf2; however, further identification of Nrf2 activators for liver injury/failure and Nrf2 inhibitors for viral hepatitis, and HCC is promising for the establishment of extensive and effective approaches to improve the prognosis of liver diseases. This evidence concerns the gene NFE2L2 and liver disorder.